Flexible, app-based technology
The future of healthcare is smaller, faster and more accessible. The ready availability of standard mobile hardware such as tablets and smartphones by front line medical care providers is a revolution in medical care. Today smartphones and tablets are capable of being used for much more than just entertainment. For the medical world, this means easy, low cost access to a wider variety of decision-making tools than ever before.
One of our design principles is to support the shift in healthcare technology to flexible platforms and broader collaboration. This is why we built our technology to support a flexible and scalable wireless app-based platform. Biim will offer feature-rich ultrasound scanning hardware and software that matches the simplicity and ease of use expected by any standard tablet users. The Biim probe connects easily with WiFi to a tablet to generate quality images.
Strategy
We will offer a high quality, ultraportable, cordless and easy to use ultrasound imaging system that is affordable and attractive for medical frontline applications. This powerful combination is attractive to both established and emerging user groups, with the potential to make the ultrasound scanner the new visual stethoscope - and much more.
Tablet-linked ultrasound scanning is becoming an established practice. It will act as the foundation for a virtual medical dashboard for tablet-based devices.
Nordic roots, cross-Atlantic presence
Biim is headquartered in Narvik, Norway, and has operations in Norway, Finland and the USA. We chose to build a company with a deep presence in both Europe and the USA, which represent the largest potential markets for our products. Our unit in Oulu, Finland is responsible for developing applications (apps) and software, while the units in Narvik, Norway, Boca Raton and Seattle, USA are responsible for hardware development, regulatory, production and distribution.
Investors
Biim is mainly owned by private investors from Norway and the U.S.A, employees as well as an institutional investor.
As of January 2018, Biim has raised approximately $12 million in funding. This has allowed the company to complete the necessary development processes prior to seeking FDA clearance and CE mark.
Management
Rune Nystad
Founder
Former manager at Boston Scientific, involved in multiple successful start-ups and over 30 product launches. Has over 17 years international business experience and has raised more than 25 million USD in venture capital, soft funding and government loans/grants.
History
From an idea to a company:
December 2012 – June 2013: Initial exploration of the wireless ultrasound concept
July 2013: Initial funding
September 2013: Exclusive patent rights are secured
Creating a management team:
March 2014: Additional funding
April 2014: Rune Nystad appointed as CEO
August 2014: Brian Scovil (ex-Boston Scientific executive) appointed as Chairman of the Board of Directors
The first prototype and growth:
October 2014: EyeLife Inc. established in the USA
January 2015: EyeLife Oy established in Oulu, Finland, with software development as its main responsibility
February 2015: First wireless prototype demonstrated with an ultrasound image on a tablet
June 2015: Generation 2 prototype with the accompanying software completed
August 2015: Further patents filed
September 2015: Generation 3 prototype completed
January 2016: Generation 4 prototype completed
Expert team joins:
July 2016: Jens U. Quistgaard is appointed Member of the Board and the Seattle product development group is established
December 2016: Generation 5 prototype completed
Name change and a new brand:
February 2017: EyeLife becomes Biim Ultrasound and the brand Biim is introduced
New hires and FDA Clearance:
June 2017: Brian Scovil appointed CTO, COO and regulatory responsible.
October 2017: Biim Ultrasound receives a 510(k) clearance from FDA for the Biim linear probe and the Biim app.
Partnership and market launch:
December 2017: Sales and distribution agreement signed with AngioDynamics Inc.
March 2018: Launch of the first product in USA
Observe Medical:
March 2022: Observe Medical completes acquisition of Biim Ultrasound.
March 2022: Rune Nystad appointed CEO of Observe Medical ASA
April 2022: Observe Medical successfully delivers Biim Ultrasound probes to all of Fresenius Kidney Care's educational centers in the USA.
Contact:
Investment/ Regulatory
Sales USA
Technology
Marketing
USA Office
Jobs and careers
Interested in joining Biim, but can't find a specific job opening that suits you? Please get in touch and send us your open application.